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ABSTRACT
We have shown that galectin-1 and galectin-3 are
functionally redundant splicing factors. Now we
provide evidence that both galectins are directly
associated with spliceosomes by analyzing RNAs
and proteins of complexes immunoprecipitated
by galectin-specific antisera. Both galectin antisera
co-precipitated splicing substrate, splicing inter-
mediates and products in active spliceosomes.
Protein factors co-precipitated by the galectin anti-
sera included the Sm core polypeptides of snRNPs,
hnRNP C1/C2 and Slu7. Early spliceosomal com-
plexes were also immunoprecipitated by these
antisera. When splicing reactions were sequentially
immunoprecipitated with galectin antisera, we found
that galectin-1 containing spliceosomes did not
contain galectin-3 and vice versa, providing an exp-
lanation for the functional redundancy of nuclear
galectins in splicing. The association of galectins
with spliceosomes was (i) not due to a direct
interaction of galectins with the splicing substrate
and (ii) easily disrupted by ionic conditions that had
only a minimal effect on snRNP association. Finally,
addition of excess amino terminal domain of
galectin-3 inhibited incorporation of galectin-1 into
splicing complexes, explaining the dominant-
negative effect of the amino domain on splicing
activity. We conclude that galectins are directly
associated with splicing complexes throughout the
splicing pathway in a mutually exclusive manner
and they bind a common splicing partner through
weak protein–protein interactions.
INTRODUCTION
Before transport to the cytoplasm for translation, RNA
transcripts in the form of pre-mRNA assemble into a
macromolecular structure termed the spliceosome. During
subsequent remodeling events of spliceosomes, introns are
removed and exons are ligated to form mature mRNA.
In vitro cell-free assays using simple splicing substrates and
nuclear extracts (NE) have established the basic sequence
of biochemical events and ordered series of complexes in
the pathway (1–4). In this dynamic, multi-step process, over
300 proteins and ﬁve ribonucleoprotein particles (snRNPs)
orchestrate two trans-esteriﬁcation reactions that result in the
formation of mRNA (5–9). We previously identiﬁed two poly-
peptides in NE from HeLa cells (galectin-1 and galectin-3)
required for splicing (10,11). Depletion of both galectins
from NE, either by lactose–agarose afﬁnity or double antibody
adsorption chromatography, abolished splicing activity and
halted spliceosome assembly at an early step. Addition of
either galectin restored both splicing activity and spliceosome
formation. These data suggested that galectins are, indeed,
splicing factors and that they are functionally redundant.
Galectins are a family of carbohydrate-binding proteins
with speciﬁcity for galactose or galactose-containing glyco-
conjugates that localize both intracellularly and extra-
cellularly (12). Two of the galectins (galectins-1 and -3) are
ubiquitous in mammalian tissues and have been documented
in the nucleus and cytosol. Galectin-1 (gal-1) is composed of
a single carbohydrate recognition domain (CRD) of  130
amino acids. Galectin-3 (gal-3) has an N-terminal domain
(ND) of  130 amino acids containing multiple repeats of the
amino acid sequence PGAYPGXXX of unknown function
fused to a CRD whose sequence is conserved when compared
to the CRD of gal-1 and the other galectins. As we investi-
gated the role of gal-1 and gal-3 in splicing, we noted several
key differences. First, recombinant gal-3 is  5–10 times
more efﬁcient at reconstitution of splicing than gal-1 or the
isolated CRD of gal-3 (11). Second, although both galectins
co-localize with known splicing factors (i.e. the Sm core
polypeptides of snRNPs and SC35) and each other in nuclear
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isolated ND of gal-3 inhibits splicing chemistry and spliceo-
some formation in a dominant negative manner when added
to splicing competent NE (14).
Although these data are consistent with galectins being
splicing factors, they do not address whether their role
in splicing is direct or indirect. In this study, we provide
evidence for a direct role of galectins in the splicing
pathway by showing that galectin-speciﬁc antibodies co-
immunoprecipitate pre-mRNA, splicing intermediates and
products throughout the entire splicing pathway. We have
investigated various characteristics of galectin incorpora-
tion into spliceosomes and conclude they interact via weak




Polyclonal rabbit antiserum against recombinant rat gal-1
was a gift from Doug Cooper (University of California,
San Francisco, CA, USA) (14). Additionally, we raised a
second polyclonal rabbit antiserum against recombinant
human gal-1 expressed as a fusion protein with glutathione
S-transferase (GST). A human gal-1 cDNA clone was kindly
provided by Jun Hirabayashi (15). The gal-1 cDNA insert
was isolated after BamH1 digestion and inserted into
pGEX-2T. Following expression in DH5a, the fusion protein
was puriﬁed by glutathione–agarose afﬁnity chromatography
and used to immunize rabbits. Several polyclonal rabbit anti-
sera to murine gal-3 were produced as described in Agrwal
et al. (16). When used in immunoprecipitation experiments
(Figures 4 and 6), each galectin antiserum was mono-speciﬁc
for a galectin (i.e. anti-gal-1 precipitated only gal-1 from
splicing reactions and anti-gal-3 precipitated only gal-3).
Human autoimmune serum (ENA anti-Sm) was purchased
from The Binding Site. Anti-Slu7 antibodies were purchased
from Santa Cruz Biotechnology and anti-Ran antibodies from
BD Biosciences. A monoclonal antibody against hnRNP
C1/C2 (4F4) was provided by Gideon Dreyfuss (University
of Pennsylvania). For immunoprecipitation experiments,
all antibodies were covalently cross-linked to protein
G-Sepharose fast ﬂow 4B beads (Sigma) as previously
described (11,14) generally using a 2:1 ratio of antiserum
to protein G beads.
Co-immunoprecipitation of
32P-labeled-MINX RNAs
Splicing reactions containing 60% by vol. HeLa NE were
assembled with
32P-MINX RNA without or with ATP
(1.5 mM) and creatine phosphate (20 mM) and incubated
at 30 C for the times indicated as previously described
(10,11,14). HeLa cells were obtained from the National
Cell Culture Center. Typically 60–100 ml of the splicing reac-
tion mixture was diluted to 0.5 ml with 60% buffer D (D60)
and incubated with 30–50 ml antibody cross-linked protein
G-Sepharose beads at 4 C for 1–2 h. After washing with
D60 containing 0.05% Triton X-100 (three washes, each
with 1 ml buffer), the bound material was eluted with 20 ml
of SDS–PAGE sample buffer. The eluted sample was divided
into two aliquots. RNA was puriﬁed from one by incubating
at 37 C for 20 min with proteinase K (4 mg/ml ﬁnal concen-
tration) and diluting to 100 ml with 125 mM Tris (pH 8),
1 mM EDTA, 300 mM sodium acetate. RNA was extracted
with 200 ml of phenol–chloroform (50:50 [vol/vol]), followed
by 200 ml of chloroform. RNA was precipitated with 300 ml
of ethanol at  80 C. The extracted RNA was dissolved in
10 ml of sample buffer (9:1/formamide:bromophenol blue)
and subjected to electrophoresis through 13% polyacrylamide
(bisacrylamide–acrylamide 1.9:50 [wt/wt])-8.3 M urea gels.
The radioactive RNA species were revealed by autoradiogra-
phy and quantitated by phosphorimage analysis (Molecular
Dynamics). The other aliquot was subjected to electrophor-
esis in 12.5% or 15% SDS–PAGE (bisacrylamide–acrylamide
0.9:30 [wt/wt]) and analyzed by western blotting.
The salt sensitivity of the association of galectins and
snRNPs with spliceosomes was determined as follows. Active
splicing complexes (incubated for 60 min with ATP at 30 C)
were incubated with antibody-coupled beads. Following
the initial binding, the beads were washed either with 60,
130 or 250 mM KCl-containing buffer and the bound material
was eluted with SDS–PAGE sample buffer. The RNA was
extracted and analyzed by denaturing gel electrophoresis as
described above.
Native gel electrophoresis
To evaluate binding of the galectins to the splicing substrate,
recombinant gal-1 or recombinant gal-3 (expressed in DH5a
and puriﬁed by lactose–agarose afﬁnity chromatography), or
NE was incubated with 32P-MINX under splicing conditions.
Following incubation, the reactions were subjected to native
gel electrophoresis (4% polyacrylamide gels [bisacrylamide:
acrylamide 1:80 wt/wt]) (17) and complex formation revealed
by autoradiography. Agarose native gel electrophoresis to
identify H or E complexes was performed as described by
Das et al. (18) followed by autoradiography.
RESULTS
Galectins-1 and -3 are associated with spliceosomes
Previously we showed that depletion of gal-1 and gal-3 from
HeLa NE abolished pre-mRNA splicing and arrested spliceo-
somes before formation of active complexes (i.e. only early
complexes formed) (10). Addition of either recombinant
gal-1 or gal-3 to the galectin-depleted NE resulted in recon-
stitution of splicing activity and active spliceosome formation
(10,11). We concluded that these two nuclear galectins are
redundant splicing factors. However, there was little infor-
mation to suggest whether their involvement in the splicing
pathway was direct or indirect.
To test for a direct association of galectins with spliceo-
somes, we determined whether radiolabeled splicing substrate
in splicing complexes could be precipitated by galectin-
speciﬁc antisera. As seen in Figure 1 (lane 1), after incubation
in HeLa NE with ATP for 60 min, the
32P-MINX splicing
substrate is converted to processing intermediates and prod-
ucts. Typically, 20–35% of the RNA detected following
60 min is ligated product. In the absence of ATP, no process-
ing of the MINX substrate occurs (see below). When splicing
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cipitated by galectin-speciﬁc antisera, all species of RNA, the
pre-mRNA substrate, the intermediates and the mature prod-
ucts, are found in the precipitates (lanes 4 and 5). In contrast,
pre-immune serum did not precipitate signiﬁcant quantities of
labeled RNA (lane 2). Human autoimmune serum reactive
against the Sm polypeptides of the snRNPs precipitated
all species of radiolabeled spliceosomal-associated MINX
as expected (lane 3). Thus, gal-1 and gal-3, like Sm proteins,
are associated with active spliceosomes.
To characterize in greater detail galectin-containing
splicing complexes, splicing reactions were subjected to anti-
serum selection during a time course experiment and RNAs
(Figures 2 and 3) and some of the proteins (Figure 4) in the
immunoprecipitates were characterized. Each galectin anti-
sera co-immunoprecipitated the splicing substrate throughout
the time course of the splicing reaction. At the earliest times
sampled, both antisera precipitated MINX pre-mRNA, most
probably in the form of H/E complexes (see below). Splicing
intermediates and ligated exons were precipitated as they
appeared during the kinetic analysis (Figure 2, beginning
at 20 min for the anti-gal-1 time course and at 40 min for
the anti-gal-3 time course). Less spliceosomal RNAs were
precipitated in the gal-3 time course compared to the gal-1
time course in this experiment due to use of a lower quantity
of anti-gal-3 serum for precipitation. An internal control for
the speciﬁcity of RNA precipitation is apparent in these anal-
yses. Degraded RNAs of the gal-1 time course observed at 0,
5 and 10 min (highlighted by arrows to the left of the input
lanes in Figure 2) are not detected in the immunoprecipitated
complexes at these times. Both galectin antisera appeared to
immunoprecipitate the excised lariat RNA species preferen-
tially (compare the ratios of lariat to pre-mRNA species in
the precipitates and in the input at the 40 and 60 min time
points in Figure 2). Both observations (i.e. no precipitation
of degraded RNAs and preferential precipitation of free
lariat) argue against non-speciﬁc adsorption of radioactive
RNA species to beads since the precipitated RNAs do not
reﬂect the same relative amounts of the different RNA spe-
cies in the sample used for immunoselection (input).
Detecting MINX pre-mRNA in galectin immunoprecipi-
tates at early times in the splicing reaction prompted us to
Figure 2. Time course analysis of spliceosomal RNAs precipitated by anti-gal-1 or anti-gal-3 antiserum.
32P-MINX was incubated with ATP in NE at 30 C.
At the times indicated, the reactions were subjected to galectin affinity adsorption and the bound fraction separated into two parts. RNA was extracted from one
portion and analyzed by denaturing gel electrophoresis. MINX RNA in splicing reactions at 0, 5, 10, 20, 40 and 60 min (input) and MINX RNA precipitated by
anti-gal-1 or anti-gal-3 antiserum. Arrows at left indicate degraded RNA species in the input material.
Figure 1. Analysis of spliceosomal RNA species immunoprecipitated by
variousantisera. Equal aliquots of splicing reactions incubated for 60 min with
32P-MINX and ATP were subjected to antibody adsorption and the bound
RNA analyzed by denaturing gel electrophoresis and autoradiography. Lane 1,
RNA in the splicing reaction subjected to immunoprecipitation; lane 2, RNA
bound to pre-immune serum; lane 3, RNA bound to anti-Sm; lane 4, RNA
bound to anti-gal-1 and lane 5, RNA bound to anti-gal-3. The positions of the
various RNA species are diagrammed on the right in this and subsequent
figures analyzing spliceosomal RNAs.
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acterized as H or E splicing complexes. H complexes form
upon addition of a substrate to a splicing extract even when
incubated on ice. Following incubation at elevated tempera-
tures, H complexes are converted to E (early) complexes
that are the immediate precursors of active spliceosomes.
Neither H nor E complex assembly requires ATP (18). To
test for galectin association with these two complexes,
MINX pre-mRNA was incubated without ATP in NE at
30 C for 0 min to assemble H complexes or 20 and 40 min
to chase H complexes into E complexes. Figure 3A shows
MINX pre-mRNA formed H complexes upon addition
to NE (lane 1). Nearly all of the MINX RNA was chased
into E complexes following incubation for 20 and 40 min
at 30 C (lanes 2 and 3). In a time course experiment, anti-
gal-1 antiserum immunoprecipitated splicing competent pre-
mRNA assembled in H complexes at 0 time (Figure 3B,
lane 5) and E complexes after 20 through 60 min of incuba-
tion at 30 C (Figure 3B, lanes 6–8). Thus, complexes formed
in the absence of ATP with mobilities characteristic of H and
E pre-splicing complexes contain gal-1. Similar results for
gal-3 were obtained (data not shown).
To conﬁrm further that the immunoprecipitated complexes
represented spliceosomes, antisera speciﬁc for several splic-
ing factors were used to probe the precipitated fractions
(Figure 4). Antiserum speciﬁc for gal-1 co-precipitated the
Sm B/B0 core polypeptides of snRNPs, hnRNP C1/C2 and a
factor required for in the second trans-esteriﬁcation reaction
Slu7. In contrast, gal-3 was not detected in the anti-gal-1 pre-
cipitate. We have also tested for and failed to ﬁnd other
nuclear proteins such as Ran co-immunoprecipitated by
anti-gal-1 (data not shown). As expected, gal-1 antiserum
precipitated gal-1. Similar results were obtained when the
immunoprecipitates of anti-gal-3 antiserum were analyzed
by western analysis (data not shown).
Galectins should be detected in spliceosomes isolated by
precipitation with antiserum directed against another splicing
factor. A reciprocal co-immunoprecipitation experiment was
performed using anti-Sm antisera (Figure 5). As expected,
spliceosomes selected by the Sm antiserum contained the
splicing substrate, intermediates and products. Immunopre-
cipitation with human IgG revealed only background levels
of splicing RNAs. Most importantly, gal-1 was detected in
the Sm selected complexes, but not detected in the material
precipitated by the control human IgG. These data strongly
support our contention that galectins are splicing factors
associated with the splicing machinery.
Galectin-1 and galectin-3 reside on distinct
splicing complexes
Spliceosomes selected by galectin-speciﬁc antisera are a
heterogeneous mixture of complexes (e.g. spliceosomes con-
taining pre-mRNA substrate would be expected to contain
different RNA and protein components than spliceosomes
Figure 3. Immunoprecipitation of
32P-labeled RNA assembled into early (H and E) complexes. (A) MINX RNA was incubated with NE at 30 C in the absence of
ATP for the indicated times. The reaction mixtures were loaded directly onto 1.5% agarose gels. Following electrophoresis, autoradiography was performed to
detect RNA-containing complexes. (B) Splicing reactions containing MINX RNA in the absence of ATP at 0, 20, 40 and 60 min incubation at 30 C (lanes 1–4)
were incubated with anti-gal-1 immobilized and the bound material subjected to analysis by denaturing gel electrophoresis (lanes 5–8).
Figure 4. Analysis of proteins co-immunoprecipitated by gal-1 antiserum.
HeLa NE (NE) and bound fractions from anti-gal-1 immunoprecipitates
(aG1) were blotted for Sm B/B0, hnRNP C1/C2, Slu7, gal-1 and gal-3.
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most of the proteins in spliceosomes has not been determined,
it is assumed that under standard splicing conditions using a
single splicing substrate each distinct processing pathway
intermediate will contain the same complement of proteins.
Thus, it is reasonable to predict that spliceosomes containing
gal-1 would also contain gal-3. However, in our previous
depletion–reconstitution studies, we showed that either gal-
1 or gal-3 could restore splicing activity to a galectin-
depleted NE. Obviously, under these reconstitution condi-
tions, spliceosomes containing a galectin would contain
only that particular member of the galectin family.
To distinguish between these two formal possibilities
(spliceosomes precipitated by one galectin antibody contain
one or both nuclear galectins), we performed sequential
immunoprecipitations as outlined in Figure 6A. Standard
splicing reactions were incubated for 60 min. and divided
into two equal portions. One aliquot was immunoprecipitated
with anti-gal-1 and the other with anti-gal-3. The unbound
fractions were then subjected to a second immunoprecipita-
tion using the other galectin antiserum. Radiolabeled RNA
in the bound fractions from each immunoprecipitation was
analyzed (Figure 6B). Roughly the same quantity of spliceo-
somes was precipitated by the anti-gal-1 antiserum in the
two sequential selections (compare lanes 3 and 10). Similar
results were obtained following the two anti-gal-3 immuno-
precipitations (compares lanes 4 and 8). In order to interpret
these results, the efﬁciency of each galectin antiserum
to quantitatively immunoprecipitate its cognate antigen was
determined. We analyzed the bound and unbound frac-
tions from the ﬁrst immunoprecipitation for gal-1 and gal-3
(Figure 6C). The bound fraction from the ﬁrst anti-gal-1
precipitate showed only gal-1 (Figure 6C, lane 3) with no
detectable gal-3. Further, the unbound fraction of this precip-
itation showed nearly quantitative depletion of gal-1 (lane 6;
the amount of gal-1 in this fraction represents <10% of
the total gal-1 in the reaction used for immunoprecipita-
tion). Similar results were obtained with gal-3. Analysis
of the bound fraction of the ﬁrst anti-gal-3 precipitation
showed only gal-3 (lane 4) and nearly all of gal-3 was
removed by this immunoprecipitation (lane 5; <15% of
the total gal-3 in the reaction remained in the unbound
fraction of the ﬁrst precipitation). We interpret these
data to indicate that gal-1 and gal-3 were quantitatively
removed during the initial immunoselection and that the
two galectins reside on different splicing complexes.
Finally, spliceosomal RNAs could be immunoprecipitated
by anti-Sm serum from the material remaining after the
two sequential galectin adsorptions (data not shown), indi-
cating that some spliceosomal complexes contained neither
gal-1 nor gal-3.
As an additional evaluation of the nearly quantitative and
speciﬁc removal of each galectin by its respective antiserum,
this experiment was repeated with the following modiﬁcation.
The unbound fraction of the ﬁrst immunoprecipitation was
incubated with the same antiserum as that used in the ﬁrst
antibody selection (i.e. unbound material of anti-gal-1 precip-
itation was rebound to anti-gal-1 coated beads). Less than 5%
of the initially precipitated RNA was bound to the antiserum
in the second round of precipitation (data not shown). This
low level of binding to the same antiserum matched the
low levels of galectin found in the unbound material after
the ﬁrst precipitation.
It is important to note that these results provide another
control for the speciﬁcity of the spliceosomes precipitated
by the anti-galectin antisera. The fact that each galectin
antiserum precipitates only its respective antigen indicates
that these antibodies do not precipitate nuclear proteins/
complexes non-speciﬁcally and further suggests that galectins
do not bind to splicing complexes non-speciﬁcally.
Figure 5. Immunoprecipitation of spliceosomes by anti-Sm antiserum. Splicing reactions were incubated with ATP for 60 min. and then were
immunoprecipitated with human anti-Sm antiserum or human IgG (control). Bound fractions were eluted and RNA analyzed by gel electrophoresis and
autoradiography (A) and gal-1 detected by western blotting (B).
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MINX RNA directly
The ﬁndings described above could be explained by a direct
interaction of the galectins with the MINX pre-mRNA. If this
interaction was with a unique site in the pre-mRNA, then
only one galectin would bind per pre-mRNA and spliceo-
somes containing this pre-mRNA would have either gal-1
or gal-3 associated. To test for direct galectin–MINX
interactions, we used an electrophoretic mobility shift assay
(Figure 7).
32P-MINX RNA migrated in native polyacry-
lamide gels as shown in lane 1 of Figure 7A and B. Incuba-
tion of MINX with recombinant human gal-1 (0.5 or 2.5 mg,
Figure 7A, lanes 2 and 3, respectively) or recombinant gal-3
(0.8 or 4 mg, Figure 7B, lanes 2 and 3, respectively) did not
alter the mobility of MINX when compared to the mobility of
the substrate alone. Various incubation conditions
(i.e. changing temperature, time of incubation and incubation
with or without ATP) yielded the same results. As a positive
control for altered mobility, MINX was incubated with NE
for 15 min on ice. As expected, MINX was assembled into
an H complex that had a slower mobility in the native gel
(lane 4 of Figure 7A and B). We conclude that the association
of galectins with spliceosomes occurs through interaction
with another splicing component rather than through direct
binding to the splicing substrate.
ND of gal-3 blocks gal-1 association with spliceosomes
Splicing activity in a complete HeLa NE is inhibited in a dose
dependent manner by the addition of the ND of gal-3. At the
highest concentration of ND, neither splicing activity nor
spliceosome complex formation could be detected even
though gal-1 was available (14). Our ﬁnding that each galec-
tin resides on separate splicing complexes suggests a mecha-
nism for this dominant negative effect of the ND. Splicing
Figure 6. Sequential immunoprecipitation of splicing complexes by gal-1 and gal-3 antisera. (A) protocol for sequential immunoprecipitation. Splicing reactions
were incubated for 60 min with
32P-MINX and divided into equal aliquots. The aliquots were incubated with the indicated antiserum as described in Materials
and Methods. Part of the unbound fraction was then incubated with the other galectin antiserum. After washing, the bound material from the first and second
immunoprecipitations was eluted and analyzed for MINX RNA (B). Lanes 1, 5, 7 and 9 represent aliquots of the bound fraction used for immunoprecipitation
(input). Lanes 2–4, represent the MINX RNA bound to the indicated antiserum in the first immunoprecipitate and lanes 6, 8 and 10 represent MINX RNA bound
to the indicated antiserum in the second immunoprecipitate. (C) western blotting analysis of gal-1 and gal-3 in the bound (lanes 2–4) and unbound (lanes 5–7)
fractions of the first immunoprecipitation.
Figure 7. Native gel analysis of splicing substrate incubated with
recombinant gal-1, recombinant gal-3 or NE. (A)
32P-MINX was incubated
on ice for 15 min with 0.5 (lane 2), 2.5 (lane 3) mg recombinant human gal-1,
HeLa NE  25 mg protein (lane 4), or nothing (lane 1). (B)
32P-MINX was
incubated on ice for 15 min 0.8 (lane 2), 4.0 (lane 3) mg recombinant gal-3,
HeLa NE  25 mg protein (lane 4) or nothing (lane 1). Following incubation,
heparin was added and the samples analyzed on 4% polyacrylamide native
gels followed by autoradiography. The migration of free MINX RNA and
MINX RNA in H complexes (indicated between the two panels) was detected
by autoradiography.
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this partner is shared by the galectins in a mutually exclusive
manner. We suggest that excess ND binds to this partner
and blocks the interaction of this partner with both nuclear
galectins. To test this prediction, we quantitated spliceosomes
immunoprecipitated by anti-gal-1 antiserum in reactions
inhibited by the ND of gal-3 (added as a GST fusion protein).
The results are shown in Figure 8. As previously reported
(14), the GST-ND polypeptide inhibited product formation
nearly 100% (lane 5) compared to reactions incubated with
(lane 3) or without (lane 1) GST. The addition of GST to
the reaction did not inhibit the precipitation of spliceosomes
by anti-gal-1 (compare lane 4 to lane 2). In contrast, the
addition of GST-ND nearly completely inhibited the associa-
tion of gal-1 with the splicing machinery (compare lane 6 to
lanes 2 and 4). Thus, the ND of gal-3 exerts its dominant
negative effect by regulating the incorporation of gal-1
(and gal-3) into splicing complexes.
Galectin association with spliceosomes is salt labile
The strength of the association of galectins with spliceosomes
was evaluated in relation to the stable association of the
snRNPs with splicing complexes. Splicing complexes formed
after a 60 min. splicing reaction (Figure 9, lane 1) were incu-
bated with each galectin antiserum or pre-immune serum in
60 mM KCl buffer (the buffer used for optimal splicing efﬁ-
ciency). Aliquots of the antibody-bound spliceosomes were
then washed with 60 mM (lanes 2–5), 130 mM (lanes 6–9)
or 250 mM (lanes 10–13) KCl buffers. The bound fractions
were eluted and analyzed for radiolabeled RNA. Salt con-
centrations of 130 or 250 mM released most of the splicing
substrate from the galectin-selected columns (>90% of the
spliceosomes were released as determined by quantitation
from phosphorimage analysis) whereas 130 mM KCl had
no effect on spliceosomes selected by anti-Sm antiserum.
Even when the salt was increased to 250 mM KCl,  20%
of the snRNPs remained stably associated with spliceosomes.
The loss of spliceosomal RNAs from the antibody columns
was due to dissociation of the complexes from each galectin
and not due to release of the galectins from their respective
antibody. At 130 mM KCl, virtually no gal-1 or gal-3 was
released from the immobilized antibodies compared to the
galectins bound at 60 mM KCl. At 250 mM KCl, more
than 70% of the galectins remained bound to the antibodies
(data not shown). We conclude that the association of galec-
tins with the splicing machinery is sensitive to perturbation of
ionic strength.
Figure 9. Analysis of spliceosomes precipitated by various antisera at increasing salt concentrations. HeLa NE was incubated with
32P-MINX for 60 min in the
presence of ATP. Immobilized pre-immune serum (lanes 2, 6 and 10); anti-gal-1 (lanes 3, 7 and 11); anti-gal-3 (lanes 4, 8 and 12) or anti-Sm (lanes 5, 9 and 13)
was incubated with the reactions in 60 mM KCl-buffer for 60 min. Beads were then washed extensively with 60 mM KCl-buffer (lanes 2–5); 130 mM KCl-buffer
(lanes 6–9); or 250 mM KCl-buffer (lanes 10–13). The bound fractions were eluted and RNA analyzed by denaturing gel electrophoresis and quantitated by
phosphorimage analysis (Molecular Dynamics) following autoradiography. Lane 1 indicates the RNA subjected to immunoprecipitation.
Figure 8. Analysis of spliceosomes immunoprecipitated by anti-gal-1
antiserum in reactions incubated with GST or GST-ND of gal-3. Equivalent
splicing reactions were incubated with no addition (lane 1, input), GST
(lane 3, +GST: input, 100 mM) or GST-ND (lane 5, +GST-ND: input,
100 mM) for 60 min. Anti-gal-1 beads were added to each reaction and RNA
in the bound fractions was analyzed by gel electrophoresis and autoradio-
graphy (lanes 2, 4 and 6).
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We previously have shown by depletion–reconstitution
experiments that galectins-1 and -3 are required splicing
factors (10,11). Further, the splicing activity of the galectins
appears to be redundant in that either galectin can reconstitute
splicing in a galectin-depleted NE. Now we document a
direct association of these galectins with spliceosomal
complexes. The key ﬁndings are (i) mono-speciﬁc galectin
antisera immunoprecipitate splicing substrate RNAs in H, E
and active spliceosomes along with Sm proteins of snRNPs,
hnRNP C1/C2 and Slu7 (all known splicing factors),
(ii) spliceosomal complexes contain either gal-1, gal-3 or no
galectin (iii) neither galectin interacts directly with the pre-
mRNA substrate, (iv) the amino terminus of gal-3 exerts a
dominant negative effect on splicing by regulating the entry
of gal-1 (and presumably gal-3) into splicing complexes
and (v) the association of galectins with spliceosomes is
salt-sensitive compared to the stable association of the
snRNPs.
The data presented are signiﬁcant in evaluating the role of
galectins as splicing factors. First, these data support our
hypothesis that nuclear galectins are indeed splicing factors
that can be incorporated into the canonical model for pre-
mRNA splicing (1). The fact that both galectin antibodies
co-immunoprecipitate pre-mRNA associated with early (i.e.
H and E) complexes illustrates the initial entry of galectins
during spliceosome assembly. While a precise molecular
function of galectins during spliceosome assembly is not
known, it appears to be in the recruitment or supplying of
snRNPs to pre-mRNA based on two observations: (i) deple-
tion of galectins from splicing extracts inhibits transition of
early (e.g. H and/or E) complexes to active spliceosomes
(1) and (ii) galectins are associated with gemin4 in SMN
complexes (14) which are implicated in recycling snRNPs
to pre-mRNA in the early commitment complex (19).
Since the anti-galectin antibodies precipitated not only
the pre-mRNA substrate but also the intermediates and prod-
ucts of the splicing reaction generated on the spliceosome,
our results suggest that gal-1 and gal-3 are associated with
the assembled machinery throughout the reaction cycle. It
is clear that these galectin-containing complexes are spliceo-
somes as the hnRNP C1/C2 polypeptides [known splicing
factors (5–9,20)], the snRNP-speciﬁc Sm proteins and Slu7
(2,5–9) co-precipitate with the substrate intermediates and
products. Results of three controls strengthen our interpreta-
tion of the data. First, the nuclear shuttling protein Ran,
which has not been found associated with spliceosomes, is
not co-precipitated by the galectin antisera. Second, gal-1-
containing spliceosomes are not precipitated by antibodies
speciﬁc for gal-3 and vice versa. These results indicate
(i) the galectin antisera are mono-speciﬁc and (ii) galectins
do not adhere non-speciﬁcally to splicing complexes. Third,
spliceosomes isolated by precipitation with antibodies dir-
ected against the Sm polypeptides of snRNPs co-precipitate
galectins.
An obvious question of our contention that galectins are
splicing factors is that they have not been identiﬁed in any
of the proteomic analyses of spliceosomes (5–9). Several rea-
sons can be offered to explain this discrepancy. First, most
of the spliceosome isolation procedures use 150–250 mM
salt during binding or washing to select stable complexes.
The rationale has been to correctly identify components
with a stable association in the spliceosome, rather than cata-
logue all associations. As we have shown (Figure 9), ionic
conditions >60 mM release the galectins from spliceosomal
complexes. We contend the buffer conditions we use for
immunoprecipitation (which are optimal for in vitro splicing
activity) allow a more complete cataloguing of spliceosomal
proteins. Could the transient/loose association of galectins
hint to a regulatory role? Second, the galectins may be in
low abundance in spliceosomes. Our observation that not
all spliceosomes contain galectins speaks to this point.
Third, it is possible that galectins only assist in initiating
spliceosome assembly (i.e. only associate with a complex
containing the pre-mRNA substrate) and are not stable com-
ponents of active splicing complexes. Only a thorough and
careful evaluation of these early complexes would reveal
this association. Finally, the stringency set for the identiﬁca-
tion of peptides and subsequent database searches results in
missing members of a complex. For example, of the four
massive proteomic analyses published, none have detected
the U6-associated polypeptide LSm5 and there are several
instances where one of the four studies detected a core
spliceosomal component and the other three did not.
Other signiﬁcant aspects of our ﬁndings include providing
an explanation for functional redundancy of the galectins and
hinting at the nature of the spliceosome-associated binding
partner for the galectins. Reconstitution of a galectin-depleted
NE can be achieved by either gal-1 or gal-3 (10,11). The
sequential immunoprecipitation data provide experimental
proof for the exclusive incorporation of only a single galectin
into a splicing complex in a complete (i.e. non-depleted)
splicing extract. Thus, functional redundancy means spliceo-
somes contain only one galectin. We show that the ND of
gal-3 regulates the entry of gal-1 into spliceosomes. In aggre-
gate, these data suggest the galectins share a common binding
partner. This partner is probably a polypeptide splicing factor
that weakly interacts with the galectins. In a splicing extract,
gal-3 interacts with this partner via its two domains (the ND
which contains the PGAYPGXXX repeats of unknown func-
tion and the C-terminus which is the CRD) whereas gal-1
only binds via its single CRD. The observation that gal-3 is
8–10 times more efﬁcient in reconstituting splicing activity
in galectin-depleted extracts compared to gal-1 supports this
contention (11). Addition of excess ND binds to this common
partner and blocks binding of gal-1 or gal-3. Abrogation
of gal-1 and gal-3 binding results in inhibition of splicing.
It remains to be determined whether the galectin-binding
partner is assembled into splicing complexes when bound
to the isolated ND.
Crucial to providing a mechanistic interpretation of these
data regarding the association of galectins with spliceosomal
complexes is the identiﬁcation of the splicing partner for the
galectins. While we have identiﬁed gemin4 as a galectin
binding protein (14), neither gemin4 nor other members of
the SMN complex (19) have been identiﬁed as spliceosomal
components in proteomic analyses (5–9). Is this due to the
fact that gemin4 and interacting proteins are not spliceosomal
proteins or, as with the galectins, that they are weakly asso-
ciated with spliceosome complexes and released under the
conditions used for spliceosome isolation? From a different
Nucleic Acids Research, 2006, Vol. 34, No. 18 5173perspective, gal-1 has been shown to be a component of the
nuclear matrix (21) that has been proposed to serve as a scaf-
fold for the splicing process. The nuclear matrix partner with
which gal-1 interacts is unknown. Also, proteomic analysis of
interchromatin granule clusters (IGC) has identiﬁed a galectin
as a member of this nuclear organelle. Over 80% of the
proteins identiﬁed as IGC components play a role in RNA
biogenesis with >50% having a splicing function (22). Both
of these ﬁndings lend additional, albeit indirect, support to
our assertion that the galectins are splicing factors.
Galectin-containing spliceosomes have been precipitated
with several different galectin-speciﬁc antisera using three
conditions to assemble various splicing complexes. The
association of galectins with spliceosomes is through a salt-
sensitive protein–protein interaction rather than a galectin-
splicing substrate interaction. The commonly shared binding
partner/splicing factor explains the mutually exclusive
incorporation of gal-1 or gal-3 into splicing complexes and
the dominant negative inhibition of splicing demonstrated
by the ND of gal-3.
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